Transfusion-related acute lung injury in the critically ill: a translational approach
Vlaar, A.P.J.

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
Chapter 7

Supernatant of stored platelets causes lung inflammation and coagulopathy in a novel *in vivo* transfusion model


Blood 2010;116:1360-8
Abstract

**Background:** Transfusion–related acute lung injury (TRALI) is suggested to be a “two hit” event, resulting from priming and activation of pulmonary neutrophils. Activation may result from infusion of lysophosphatidylcholines (LysoPCs), which accumulate during storage of blood products.

**Methods:** In the present study, we developed a syngeneic *in vivo* transfusion model to test whether storage of platelet concentrates (PLTs) results in lung injury in healthy rats as well as in a “two hit” model using lipopolysaccharide (LPS)-pretreated rats. In addition, the effect of washing of platelets was studied. In healthy rats, transfusion of aged PLTs caused mild lung inflammation.

**Results:** In LPS–pretreated rats, transfusion of aged PLTs, but not fresh PLTs, augmented pulmonary and systemic coagulopathy. When PLTs components were transfused separately, supernatant of aged PLTs, but not washed aged platelets, induced pulmonary injury in the “two hit” model. Supernatants of aged PLTs contained increased concentrations of LysoPCs compared to fresh PLTs, which enhanced neutrophil priming activity *in vitro*.

**Conclusions:** We conclude that transfusion of aged PLTs induces lung inflammation in healthy rats. In a “two hit” model, aged PLTs contribute to pulmonary and systemic coagulopathy, which may be mediated by LysoPCs, which accumulate in the supernatant of PLTs during storage.
Transfusion-related acute lung injury (TRALI) is the leading cause of transfusion related morbidity and mortality.1-3 TRALI is characterized by the acute onset of hypoxia within 6 hours after transfusion of a blood product.4 Although TRALI is rarely reported in the general hospital population, the incidence is high among critically ill patients, ranging between 5.3 and 8% per transfused patient.5-7

The high incidence of TRALI in this specific patient population may be explained by the pathogenesis of TRALI, which is thought to be a “two hit” event. The “first hit” is inflicted by a pro-inflammatory pulmonary condition, e.g., pneumonia, sepsis, or lung contusion, causing activation of lung endothelium with subsequent sequestration and priming of polymorphonuclear neutrophils. The “second hit” is provided by transfusion of a blood product, resulting in degranulation and release of reactive oxygen species of the primed neutrophils and subsequent pulmonary edema. Besides antibodies against human leukocyte antigens, biologically active lipids (lysophosphatidylcholines, LysoPCs) and cytokines, which are released and accumulate during storage of platelets products, have been implicated in the pathogenesis of TRALI.8-10

Transfusion of (aged) platelet concentrates (PLTs) was found to be associated with the onset of TRALI and adverse outcome.5-7 Mechanisms of the detrimental effect of PLTs on lung inflammation may include accumulation of soluble factors such as LysoPCs in the supernatant. Indeed, LysoPCs from the supernatant of aged PLTs were found to activate neutrophils in vitro. Also, LysoPCs have been used in “two hit” TRALI animal models.8,9,11 Alternatively to soluble factors, PLTs themselves may induce pulmonary vascular injury in TRALI. Thrombocytopenia has been observed in TRALI patients.12-14 Also in a mouse model of antibody-mediated TRALI, thrombocytopenia occurred, suggesting that platelets may be involved. In this model, neutrophils were found to capture platelets, resulting in vascular damage and lung injury, which did not occur after depletion of platelets.15 In a similar model depletion of platelets prevented onset of TRALI.16 Whether PLTs transfusion enhances this phenomenon is unknown. Also, although coagulopathy is a hallmark of acute lung injury due to other causes,17 knowledge on coagulation disorders in TRALI is limited.

The clinical relevance of existing TRALI models is hampered by cross species and ex vivo design. At present, no in vivo platelet transfusion model exists that confirms the “two hit” TRALI hypothesis.18 In this paper, we describe a novel syngeneic in vivo rat platelet transfusion model in which the effect of aged PLTs on lung injury was studied in healthy rats and in a “two hit” model using lipopolysaccharide (LPS)-pretreated rats. Besides pulmonary inflammation, markers of pulmonary coagulopathy were determined. To elucidate the mechanism of lung injury induced...
by aged PLTs, we performed additional experiments using specific components of the aged PLTs products.

**Materials and Methods**

The Institutional Animal Care and Use Committee of the Academic Medical Center and the Medical Ethical Committee of Sanquin Blood Bank Foundation approved all experiments. All animals were handled in accordance with the guidelines prescribed by the Dutch legislation and the International Guidelines on protection, care, and handling of laboratory animals.

*Preparation of rat PLTs products*

Male Sprague–Dawley rats (> 250 g, Harlan; The Hague, The Netherlands) were used to obtain blood. Rats were anesthetized with an intramuscular injection of ketamin 45 mg/kg (Eurovet; Bladel, The Netherlands) and medetomidin 0.25 mg/kg (Novartis; Arnhem, The Netherlands). Blood was collected from the *inferior vena cava* in a syringe containing 1.25 ml citrate-phosphate-dextrose (CPD, Fresenius Kabi; Emmer Compascuum, The Netherlands). Approximately 8-10 ml of blood could be obtained from a single rat. Blood of five rats was pooled for component preparation. Prior to pooling, cross-matching was carried out to ensure compatibility. Blood was handled and stored according to national standards for human blood (Sanquin Blood Supply Foundation), with minor changes to adapt for the smaller volumes. After overnight storage at room temperature, blood was centrifuged for 10 minutes at 1,892 x \( g \) and 20 °C. Plasma was removed and the buffy coat was separated from the red blood cells. The buffy coat was diluted with pooled plasma to end up with a hematocrit of about 20% (v/v) and centrifuged for 10 minutes at 288 x \( g \) and 20 °C to separate the majority of the remaining erythrocytes and leukocytes from the platelets. To enable a final platelet count in PLTs of approximately 1,000 x 10\(^9\)/L, platelet counts were performed between the separation steps. The supernatant containing the platelets was collected and stored at 22 ± 2°C horizontally shaking with 1 cycle/s (Platelet Incubator Helmer; Noblesville, Indiana, USA) in culture flasks, (Nunclon™ surface 50 ml, Nunc™, Thermo Fisher; Rochester, New York, USA) 7 ml PLTs each, under 5% CO\(_2\)/95% air mixture. Storage of aliquots of platelet concentrates in a culture bottle with 5% CO\(_2\) has been used in several studies on human platelets, resulting in similar storage conditions compared to storage in a standard platelet storage container.\(^{19,20}\)
Preparation of washed aged platelets and supernatant rat PLT products
After 5 days of storage, rat PLTs products were separated into washed platelets and supernatant. The PLTs products were centrifuged for 15 minutes at 1,250 x g and 22 °C. The supernatant of the rat PLTs product was separated. The platelets were washed using CompoSol (Fresenius Hemocare, Emmer Compascuum, The Netherlands) which was added up to the original volume and centrifuged for 15 minutes at 1,000 x g and 22 °C. The supernatant was removed and the CompoSol was added to the platelets up to the original volume of the rat PLT product. Platelet count in the final washed product was >90% of the original count.

In vivo PLTs transfusion model
Male Sprague-Dawley rats (275 g) raised on a regular diet were randomized into 3 groups (n=6 per group) to receive transfusion with saline (NaCl 0.9%), transfusion with fresh PLTs or transfusion with PLTs stored for 5 days (aged PLTs). A storage time of 5 days was chosen, because in pilot experiments, rat PLTs stored for 5 days showed storage-related changes comparable to those found in previous studies using aged human platelets stored for 5 days.9 For the experiments in the “two hit” PLTs transfusion model, rats received a “first hit” of 2 mg/kg of lipopolysaccharide (from Salmonella enteritidis, Sigma; St. Louis, Missouri, USA) intra-peritoneally two hours prior of transfusion. The animals in the other experiments received instead of LPS, saline as a “first hit” (equal volume). Animals were weighed and anaesthetized with pentobarbital 50 mg/kg intra-peritoneally. The tail vein was cannulated with a 24 gauge venflon (Vasofix Certo B.Braun; Meisungen, Germany) and blood was aspirated to verify intravascular placement and to remove 0.5 ml of blood for cross-matching and baseline measurements. A 10% circulating volume transfusion was administered over 30 minutes using an infusion pump (Harvard Pump 11, Harvard Apparatus; Holliston, Massachusetts, USA). Rats were placed back in their cages to recover and were sacrificed 6 hours after transfusion. In a separate set of experiments, LPS-pretreated and healthy animals were transfused with washed aged platelets or with supernatant of aged PLTs.

Blood and tissue sampling
After anesthesia with ketamine 45 mg/kg and medetomidin 0.25 mg/kg as described above, blood was collected from the inferior vena cava in citrated (0.109 M) vacutainer tubes for analysis and blood culture. The right lung was ligated, and the left lung was lavaged three times with 2 ml of saline. After lavage, lungs were weighed and homogenized using a tissue homogenizer (Biospec Products; Bartlesville, Oklahoma, USA). For cytokine and chemokine measurements, lung homogenates were diluted 1:1 in lysis buffer (150 nmol/l NaCl; 15 mmol/l Tris; 1
mmol/l MgCl₂–H₂O; 1 mmol/l CaCl₂; 1% Triton X-100; and 100 µg/ml pepstatin A, leupeptin, and aprotinin). The upper lobe of the right lung was fixed in 4% formalin and embedded in paraffin for histopathology examination.

**Histology and Immunohistochemistry**

Sections of 4µm were stained with hematoxylin–eosin (H&E), and analyzed by two researchers who were blinded for group identity. A histology scoring system was used as previously described. In short, the following parameters were scored on a scale of 0 – 4: interstitial inflammation, endothelialitis, bronchitis, edema, thrombus, and pleuritis. The histology score was expressed as the sum of the score for all parameters. Immunohistochemistry was performed for CD40L. Positive control was a rat spleen section stained for CD40L and CD3 (T-cell marker). Deparaffinized and rehydrated lung and spleen sections were incubated with a rat antibody against CD40L or CD3 (Abcam, Cambridge, United Kingdom) and were detected using the DAB substrate kit (Vector Laboratories, Burlingame, CA). Of each specimen, digital images were captured of five non overlapping areas (x10 objective) using a DFC500 digital camera mounted on a DM5000B microscope (both from Leica Microsystems). The area positive for CD40L was determined with Image Pro Plus (Media Cybernetics) and expressed as the percentage of the total surface area.

**Assays**

Thrombin–antithrombin complexes (TATc; Behring, Marburg, Germany) and fibrin degradation products (FDP; Asserachrom D–Di, Diagnostica Stago, Asnières–sur–Seine, France) were measured using ELISA. Plasminogen activator activity (PAA), and plasminogen activator inhibitor (PAI)–1 activity were measured by automated amidolytic assays. Tumor necrosis factor (TNF), interleukin (IL)–6, and cytokine-induced neutrophil chemoattractant (CINC)–3 were measured by ELISA according to instructions from the manufacturer (R&D Systems, Abingdon, United Kingdom). Detection limit was 62.5, 31.25 and 125 pg/ml, respectively.

**Storage-related biochemical changes in rat platelets**

PLTs samples were collected at the indicated time intervals and analyzed for pH and lactate with a Rapidlab 865 blood gas analyzer (Siemens Medical Solutions Diagnostics; Breda, The Netherlands). Cell counts for leukocytes and platelets were done with an Advia 2120 hematology counter, with special software for counting animal blood samples (Siemens Medical Solutions Diagnostics). The Kunicki morphology score, as well as the aggregation response to ADP and to the combination of ADP and collagen was measured as described. The percentage of platelets positive for Annexin V was determined as described earlier. Supernatants
were prepared by centrifugation for 10 minutes at 12,500 x g to remove cells and a-cellular debris. Aliquots of supernatants were stored at -80 °C for analysis of LysoPC, phosphatidylcholine (PC), cytokine levels and to test for neutrophil priming.

**Lipid extraction and LysoPC and PC measurement**

Lipid extraction of supernatant from PLTs supernatant was performed using the Bligh and Dyer method (chloroform:methanol:aqueous solution 1:1:1). In short, 3 ml of CHCl₃:MeOH (1:2) was added to 100 µl of sample and 100 µl of internal standard solution (LysoPC 14:0, 2.5 nmol and PC 28:0, 10 nmol). 700 µl HAc 0.5%, 1 ml CHCl₃ and 800 µl of HAc 0.5% were added. After every addition, samples were vortexed for 30 seconds. The final mixture was centrifuged for 10 minutes at 1,892 x g at room temperature. After centrifugation, the lower layer of CHCl₃ was separated. This step was repeated two times by adding 1 ml CHCl₃. The separated CHCl₃ layers were combined and dried (N₂, 30 °C). Samples were dissolved in 150 µl CHCl₃/MeOH/H₂O/ NH₃ 25% (50/45/5/0.01 v/v/v/v) for further analysis.

**HPLC tandem mass spectrometry**

LysoPCs and PC concentrations in supernatant of PLTs were determined using HPLC tandem mass spectrometry (HPLC-MS/MS). 10 µl was injected on the HPLC-MS/MS system. Chromatographic separation was achieved on a modular HPLC system (Surveyor; Thermo Finnigan, San Jose, CA, USA) consisting of a cooled autosampler (T=12°C), a low-flow quaternary MS pump and analytical HPLC column: LichroSpher Si60, 2 x250 mm column, 5 µm particle diameter (Merck, Darmstadt, Germany). Samples were eluted with a flow rate of 300 µl/min and a programmed linear gradient between solution B (chloroform-methanol, 97:3, v/v) and solution A (methanol-water, 85:15, v/v); A and B contained 1 ml and 0.1 ml of 25% (v/v) aqueous ammonia per liter of eluent, respectively. The gradient was: T = 0 -10 min: 20% A to 100% A; T = 10-12 min, 100% A; T= 12-12.1 min: 100% A to 0% A; and T= 12.1–17 min, equilibration with 0% A. Total run-time, including the equilibration, was 17 min. A splitter between the HPLC and MS was used for the introduction of the eluent in the MS by 75 µl/min.

MS/MS analyses were performed on a TSQ Quantum AM (Thermo Finnigan) operated in the positive ion electrospray ionization mode. The Skimmer Offset was set at 10 V; spray voltage was 3600 V and the capillary temperature was 300°C. In the optimized MS/MS experiments, argon was used as collision gas at a pressure of 0.07 Pa and a collision energy of 40 V. The parent ion scan of m/z 184.1 (m/z 400 - m/z 1000, 1 s) was used for the quantization of the following precursor ions: m/z 468.3 (LysoPC 14:0, I.S.), m/z 496.3 (LysoPC 16:0), m/z 524.3 (LysoPC 18:0/PAF 16:0), m/z 522.4 (LysoPC 18:1), m/z 482.4 (LysoPAF 16:0), m/z 510.4 (LysoPAF
18:0), m/z 508.4 (LysoPAF 18:1), m/z 678.4 (PC 28:0, I.S.), m/z 758.4 (PC 34:2), m/z 782.4 (PC 36:2).

**Neutrophil priming assay**
Rat neutrophils were isolated using Percoll 1.076 g/ml gradient centrifugation and NH₄Cl/KHCO₃ lysis of red blood cells. Neutrophils (1.0 x 10⁶/ml) were incubated with supernatant for 30 min at 37 °C, and thereafter activated with formyl-methionyl-leucylphenylalanine (fMLP). H₂O₂-release was measured with the fluorescent dye Amplex Red in the presence of horseradish peroxidase.

**Storage-related biochemical changes in human PLTs**
Platelet concentrates in plasma were prepared from pooled buffy coat platelets as previously described. The concentrates were filtered through a Compostop CS leukoreduction filter (Fresenius Kabi, type T3995) with a PVC-citrate container connected to the outlet of the filter. The PLTs were stored at 22 °C ± 2°C horizontally shaking with 1 cycle per minute (Helmer labs Inc, Noblesville, IN, USA), according to National Blood Bank standards. Supernatants were collected after preparation of the products and at day 5 and 7 and prepared by centrifugation for 10 minutes at 14,500 x g at 4 °C to remove cells and a-cellular debris. Aliquots of supernatants were stored at -80 °C for analysis of LysoPC and phosphatidylcholine (PC) levels.

**Statistical analyses**
Data are expressed as mean ± SEM or median with interquartile ranges, as appropriate. A paired t–test was used to compare the results of platelets before and after storage. Comparisons between the rat groups were performed using one–way ANOVA or Kruskal–Wallis test, followed by post–hoc Bonferroni’s or Dunnett’s tests, depending on data distribution. A p–value < 0.05 was considered statistically significant. Statistical analyses were performed with SPSS 12.0 (SPSS, Chicago, IL) and Prism 4.0 (GraphPad Software, San Diego, CA).

**Results**

**Effect of transfusion of aged PLTs in healthy rats**
All animals completed the experimental protocol. Blood cultures from the rats collected at the end of the experimental protocol showed no outgrowth of bacteria. Transfusion of aged PLTs induced lung injury in healthy rats, characterized by neutrophil adherence on the endothelial wall and edema in lung tissue (fig. 1).
Figure 1. Effect of transfusion of aged platelets on lung injury in healthy and primed rats. Histologic sections of hematoxylin and eosin stained rat lungs at 20x magnification. (a): Saline control, (b): Lipopolysaccharide (LPS) control, (c): Saline + fresh platelet concentrates (PLTs) day 0, (d): LPS + PLTs day 0, (e): Saline + aged PLTs (PLTs day 5), (f): LPS + PLTs day 5. Normal vasculature (arrow) (a and c) Neutrophils sequestrated in the vasculature (arrow) (b, d, f). For color figure see page 357
The histopathology score was higher compared to transfusion of fresh PLTs and saline control groups (10.6±1.1 vs. 1.7±1.6 and 2.2±2.2, p<0.05). Aged PLTs caused an increase of IL-6 and CINC-3 concentrations in the lung homogenate (p<0.05 compared to controls, fig. 2). No differences were seen between fresh or aged PLTs on markers of coagulation and fibrinolysis in neither the pulmonary (fig. 3) nor the systemic compartment (data not shown). As accumulation of soluble CD40 during storage of PLTs has been implicated in the pathogenesis of TRALI,27 CD40L was stained in the lung tissue using immunohistochemistry. After PLTs transfusion, expression of CD40L was detected on pulmonary T cells and on the endovascular wall, but no differences were observed between fresh vs. aged PLTs (fig. 4).

**Effect of transfusion of aged PLTs in LPS-primed rats**

LPS-pretreatment resulted in neutrophil sequestration in the lung endothelium and pulmonary edema, with an elevated histopathology score when compared to the saline control group (11.8±1.1 vs. 1.7±1.6 p<0.001). Also, LPS-pretreatment increased levels of IL-6 and CINC-3 in lung homogenate compared to the saline control (p<0.01, fig. 2). LPS increased pulmonary coagulation as shown by increased thrombin generation (as reflected by TATc) and increased FDP levels. In addition, fibrinolysis was impaired, as evidenced by reduced plasminogen activator activity.

---

**Figure 2.** Effect of aged platelets transfusion on cytokine and chemokine concentration in the lungs. Saline or lipopolysaccharide (LPS)-pretreated animals were transfused with saline (control), fresh platelet concentrates (PLTs day 0) or aged PLTs (day 5). Data are presented as mean±sem. *p<0.05
Figure 3. Effect of aged platelets transfusion on pulmonary coagulation and fibrinolysis. Concentrations of thrombin anti-thrombin complexes (TATc), plasminogen activator activity (PAA), plasminogen activator inhibitor (PAI-1) and fibrin degradation products (FDP) in the broncho-alveolar lavage fluid (BALF) of animals receiving saline or LPS as “first hit” and subsequently infusion of saline (control), fresh PLTs (day 0) or aged PLTs (day 5). Data are presented as mean ±sem. Aged PLTs products activate lung coagulation and decrease fibrinolysis in LPS-primed rats as shown by an increase in TATc level in the BALF and decrease of PAA% and increase of PAI-1 levels in the BALF respectively. *P< 0.05, **P<0.01, ***p<0.001.
(PAA) levels, at least in part caused by an increase in the levels of the fibrinolytic inhibitor PAI-1 compared to saline controls (p<0.01, fig. 3). LPS-pretreatment also induced systemic coagulopathy, evidenced by increased plasma TATc levels compared to saline controls (10.5±1.0 vs. 3.4±0.3 ng/ml, p<0.01).

Figure 4. Effect of transfusion of aged platelets on CD40L expression in lung tissue. Histologic sections of CD40L stained rat lungs at 20x magnification. (a): Saline control, (b): Lipopolysaccharide (LPS) control, (c): Saline + fresh platelet concentrates (PLTs) day 0, (d): LPS + PLTs day 0, (e): Saline + aged PLTs (PLTs day 5), (f): LPS + PLTs day 5. CD40L is indicated by brown staining. In all sections, except for the saline negative control, CD40L staining is present on pulmonary T-cells and on the endovascular wall (arrows). For color figure see page 358.
Transfusion of aged PLTs in LPS-primed animals had a differential effect on lung injury. Histopathology score of LPS-primed rats did not worsen after transfusion of aged PLTs compared to LPS-primed controls transfused with saline or fresh PLTs (9.3±2.0 vs. 11.8±1.1 and 10.6±1.0 resp., p=0.7, fig. 1). Pulmonary wet weight was not increased (not shown). No differences were seen for CD40L staining in the lungs between LPS-pretreated animals transfused with aged PLTs compared to animals receiving fresh PLTs (fig. 4). Aged PLTs did not increase pulmonary cytokine and chemokine levels in the “two hit” model (fig. 2). However, aged PLTs had a strong effect on pulmonary coagulopathy in LPS-primed animals, increasing BALF levels of TATc compared to fresh PLTs (p<0.001, fig. 3). Aged PLTs contributed to impaired fibrinolysis in LPS-primed animals, decreasing PAA in the BALF and increasing the level of PAI-1 compared to animals receiving fresh PLTs (p<0.001 and p<0.01 respectively). FDP levels were reduced in LPS-primed animals receiving aged PLTs compared to animals receiving fresh PLTs (p<0.05). Also, aged PLTs caused systemic coagulation, by increasing plasma TATc level compared to fresh PLTs (20.2±1.3 vs. 10.9±0.6, p<0.001).

**Effect of transfusion of washed aged platelets vs. supernatant of aged PLTs in healthy and LPS-primed rats**

To determine whether lung injury caused by aged PLTs was mediated by soluble factors in the storage medium or by the platelets themselves, aged PLTs were washed and separated from supernatant. Using these products, we repeated transfusion experiments in healthy and LPS-pretreated animals. In healthy rats, no difference was seen on lung inflammation or coagulation between animals transfused with washed aged PLTs or with supernatant of aged PLTs (fig. 5 and 6). In contrast, in LPS-primed rats, transfusion of supernatant, but not of washed aged PLTs, worsened lung coagulopathy. Supernatant of aged PLTs caused an increase in levels of TATc and decrease in %PAA in BALF compared to those receiving washed aged PLTs (p<0.01 for both, fig. 6). Also, the increase in systemic levels of TATc caused by PLT products was reproduced after transfusion of supernatant but not after transfusion of washed aged platelets (18.2±0.8 vs. 11.6±0.8, p<0.001). No effect was seen on markers of inflammation between animals receiving transfusion of supernatant or aged washed PLTs (fig. 5).

**Effect of storage time of rat PLTs on biochemical changes**

Platelet count was stable during storage. At day 0, morphology and PS-exposure were similar to that of human platelets. Also, aggregation response to ADP and to the combination of ADP and collagen was normal. At day 5 of storage, morphology changed and annexin V expression of rat platelets increased (Table 1). Also, rat PLTs
showed significant biochemical changes, exemplified by an increase in lactate levels and a decrease in pH compared to day 0 (p<0.01 for all, table 1). These storage lesions are comparable to that of human platelets stored for 7 days.24,26,28 The phenomenon of more rapid worsening of rat cells during storage was previously described for erythrocytes.29 The presence of platelet aggregates was judged by visual observation and by a hematologic cell counter. No aggregates were present until day 7 of storage for rat platelets. Concentrations of LysoPC 16:0, LysoPC 18:0/PAF 16:0 and LysoPAF 18:0 were significantly increased after 5 days of storage.
compared to day 0, with a concomitant decrease in phosphatidylcholine (PC) concentrations (p<0.05 for all, table 1). The concentration of LysoPC 18:1, LysoPAF 16:0 and LysoPAF 18:1 showed a non-significant increase of respectively 5%, 8% and 30% at day 5 storage compared to day 0 storage. IL-6 and TNF were not detectable in the supernatant of PLTs at either time point.

### Table 1. Storage-related biochemical changes in rat platelet concentrates

<table>
<thead>
<tr>
<th></th>
<th>Whole blood (fresh)</th>
<th>Platelets day 0</th>
<th>Platelets day 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>pH</td>
<td>6.9 ± 0.1</td>
<td>7.4 ± 0.1</td>
<td>6.9 ± 0.1*</td>
</tr>
<tr>
<td>Lactate (mmol/L)</td>
<td>6.2 ± 1.2</td>
<td>8.0 ± 0.3</td>
<td>21.5 ± 1.2*</td>
</tr>
<tr>
<td>Leukocytes (x 10^9/L)</td>
<td>5.4 ± 0.6</td>
<td>0.03 ± 0.01</td>
<td>0.02 ± 0.01</td>
</tr>
<tr>
<td>Platelets (x 10^9/L)</td>
<td>858 ± 48</td>
<td>1086 ± 65</td>
<td>1076 ± 76</td>
</tr>
<tr>
<td>Morphology (Kunicki score)</td>
<td>N/A</td>
<td>270±8.7</td>
<td>192±20.2**</td>
</tr>
<tr>
<td>% positive for Annexin V</td>
<td>N/A</td>
<td>4.3±0.6</td>
<td>42±1.5*</td>
</tr>
<tr>
<td>LysoPC 16:0 (µM)</td>
<td>164 ± 13</td>
<td>183 ± 17**</td>
<td></td>
</tr>
<tr>
<td>LysoPC 18:1 (µM)</td>
<td>41 ± 4.3</td>
<td>43 ± 1.6</td>
<td></td>
</tr>
<tr>
<td>LysoPAF 16:0 (µM)</td>
<td>4.5 ± 0.4</td>
<td>4.9 ± 0.1</td>
<td></td>
</tr>
<tr>
<td>LysoPAF 18:0 (µM)</td>
<td>5.1 ± 0.5</td>
<td>6.2 ± 0.4**</td>
<td></td>
</tr>
<tr>
<td>LysoPAF 18:1 (µM)</td>
<td>2.0 ± 0.4</td>
<td>2.6 ± 0.4</td>
<td></td>
</tr>
<tr>
<td>LysoPC 18:0/PAF 16:0 (µM)</td>
<td>5.1 ± 0.5</td>
<td>6.2 ± 0.4**</td>
<td></td>
</tr>
<tr>
<td>PC 34:2 (µM)</td>
<td>86 ± 11</td>
<td>46 ± 4**</td>
<td></td>
</tr>
<tr>
<td>PC 36:0 (µM)</td>
<td>23 ± 3.3</td>
<td>13 ± 0.9**</td>
<td></td>
</tr>
<tr>
<td>TNF (pg/ml)</td>
<td>&lt;62.5</td>
<td>&lt;62.5</td>
<td></td>
</tr>
<tr>
<td>IL-6 (pg/ml)</td>
<td>&lt;31.25</td>
<td>&lt;31.25</td>
<td></td>
</tr>
</tbody>
</table>

LysoPC=lysophosphatidylcholine, PAF=platelet activating factor, PC=phosphatidylcholine. TNF=tumor necrosis factor. Data are presented as mean±SD (n=5 batches). *p< 0.01. **p<0.05.

### Table 2. Storage-related changes in lysophosphatidylcholines levels in human platelet concentrates

<table>
<thead>
<tr>
<th></th>
<th>Fresh Platelets</th>
<th>Platelets day 5</th>
<th>Platelets day 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>LysoPC 16:0 (µM)</td>
<td>141±10.7</td>
<td>169±13.4**</td>
<td>192±20.8**</td>
</tr>
<tr>
<td>LysoPC 18:1 (µM)</td>
<td>32±4.6</td>
<td>34±2.8</td>
<td>36±2.8*</td>
</tr>
<tr>
<td>LysoPAF 16:0 (µM)</td>
<td>3.2±0.7</td>
<td>3.5±0.5</td>
<td>4.1±0.5*</td>
</tr>
<tr>
<td>LysoPAF 18:0 (µM)</td>
<td>4.5±0.7</td>
<td>5.2±0.6</td>
<td>6.0±1.3**</td>
</tr>
<tr>
<td>LysoPAF 18:1 (µM)</td>
<td>1.7±0.3</td>
<td>1.7±0.3</td>
<td>2.3±0.4**</td>
</tr>
<tr>
<td>LysoPC 18:0/PAF 16:0 (µM)</td>
<td>4.5±0.3</td>
<td>5.2±0.3</td>
<td>6.0±0.6**</td>
</tr>
<tr>
<td>PC 34:2 (µM)</td>
<td>122±13.2</td>
<td>115±11.9</td>
<td>105±10.0*</td>
</tr>
<tr>
<td>PC 36:4 (µM)</td>
<td>42±2.9</td>
<td>41±2.1</td>
<td>39±1.4**</td>
</tr>
</tbody>
</table>

LysoPC=lysophosphatidylcholine, PAF=platelet activating factor, PC=phosphatidylcholine. Data are presented as mean±SD (n=5 batches). *p<0.05, **p<0.01.

Supernatant of stored platelets causes lung injury.
Effect of storage time of rat PLTs on neutrophil priming capacity

Supernatant of fresh PLTs had significant neutrophil priming capacity compared to buffer control (H$_2$O$_2$ release 105.2±3.0 vs. 18.0±1.0 pmol/ml, p< 0.01, fig. 7). Storage further enhanced neutrophil priming capacity, as supernatant of PLTs stored for 2 and 5 days had higher in vitro neutrophil priming capacity compared to supernatant of fresh PLTs (H$_2$O$_2$ release 117.2±3.0 and 113.0±3.0 vs. 105.2±3.0 pmol/ml, p< 0.01, fig. 7).

Effect of storage time of human PLTs on LysoPC accumulation

In contrast to previous findings,8,9 LysoPC accumulation in aged rat PLTs products was modest in this study. Therefore, additional studies using human PLTs were performed. Comparable to our results with the rat PLTs products, concentrations of LysoPCs increased in human PLT products stored for 5 and 7 days when compared to fresh PLTs (table 2). Concentrations of LysoPC 16:0 was already increased after 5 days of storage compared to fresh concentrations, and LysoPC 18:1, LysoPAF 16:0, LysoPAF 18:1, LysoPC 18:0/PAF 16:0 and LysoPAF 18:0 were increased after 7 days of storage compared to fresh concentrations with a concomitant decrease in phosphatidylcholine (PC) concentrations (p<0.05 for all, table 2). In line with the rat PLTs product, the maximum increase in LysoPCs was around 30% compared to baseline.

Figure 7. Supernatant of aged platelet concentrates have increased neutrophil priming capacity. Neutrophil priming activity of the aged platelet concentrates (PLTs) expressed in pmol H$_2$O$_2$ release per minute per 106 neutrophils. Supernatant of fresh PLTs (Day 0) showed an increased in vitro neutrophil priming capacity compared to buffer controls. Supernatant of aged PLTs stored for 2 days and 5 days showed an increased in vitro neutrophil priming capacity compared to supernatant of fresh PLTs. *p< 0.01. Data are presented as mean±sem.
Discussion

We describe a novel in vivo syngeneic platelet transfusion model, using clinical protocols for the preparation and storage of blood products. We demonstrate for the first time that transfusion of aged PLTs cause mild pulmonary inflammation in healthy recipients. In the “two hit” transfusion model, aged PLTs augmented pulmonary and systemic coagulopathy, an effect that was mediated by supernatant of aged PLTs, but not by washed aged PLTs. Aged platelet products had increased levels of LysoPCs, with a concomitant ability to prime neutrophils. Therefore, lysoPCs accumulating in supernatant during storage of PLTs may possibly mediate TRALI in predisposed patients.

Pulmonary injury induced by aged platelets was characterized by enhanced inflammation, as shown by extravasation of neutrophils in lung tissue, a higher total pathophysiology score and an increase in IL-6 and CINC-3 in lung homogenate. These findings are in line with ex vivo animal studies which show pulmonary edema after transfusion of aged blood without previous priming of the animals.30-32 We stress that the effect of aged PLTs on lung injury was mild in this study and that pulmonary edema as a measure of pulmonary leak was absent. Results of this study need to be interpreted within the limits of the model we used. We hypothesize that aged PLTs cause inflammatory processes, which have the potential to disrupt endothelial and epithelial barriers, eventually leading to fluid accumulation within alveoli, if the pulmonary ‘hit’ is severe enough. As storage time and amount of PLTs transfused were found to be risk factors for the occurrence of ALI in the clinical setting,7,13 it may be hypothesized that repeated PLTs transfusion results in significant pulmonary injury. In patient populations that had suffered a “first hit” of trauma or cardiac surgery, transfusion of stored blood was associated with the occurrence of ALI. We speculate that mild lung injury caused by aged platelets may be augmented by subsequent “hits”.33-35

Previous studies have pointed towards a “two hit” TRALI hypothesis. However, TRALI models that were used were limited by ex vivo designs, use of blood products which were not manufactured according to clinical protocols and by the use of cross species, including human blood products which were transfused in rat recipients.9,36,37 In our syngeneic in vivo transfusion model, we confirm the “two hit” TRALI hypothesis with the use of aged PLTs.8,9,38 Our study extends previous findings, showing for the first time that aged PLTs enhance coagulation and impair fibrinolysis in the presence of primed neutrophils. Activation of coagulation and impairment of fibrinolysis have been found in ALI/ARDS due to many causes, including sterile inflammation as well as infection.17,21,39-41 From this point of view, TRALI may be regarded as part of the ALI/ARDS syndrome and not as a separate entity, as suggested before.5-7 In line with this, we recently found that TRALI contributes
to mortality in critically ill patients, suggesting that prognosis of TRALI is not as favourable as generally considered, but rather may parallel ALI due to other causes, at least in certain patient populations.5-7

Of interest, in the “two event” model, worsening of coagulopathy occurred in the absence of worsening of markers of inflammation, pulmonary edema or histopathology score. In the LPS-primed animals, extravasation of neutrophils was already elicited. Transfusion of aged platelets may have resulted in activation of these neutrophils, contributing to coagulopathy. Indeed, increased expression of P-selectin (CD62p) on the cytoplasmic surface of platelets occurs during storage, which results in binding of the aged platelets to neutrophils and monocytes after transfusion.42 Subsequently, this may directly lead to activation of coagulation. Furthermore, the endothelial response to neutrophils not only includes mediation of trafficking, but also the release of pro-coagulant factors. Pro-inflammatory cytokines stimulate expression of endothelial tissue factor, thereby eliciting the extrinsic coagulation pathway, leading to activation of coagulation.44 In accordance, a pro-coagulant state has been shown in patients with ALI.45 We speculate that coagulopathy may be an important mediator of injury in TRALI. The interaction between coagulopathy and neutrophil-mediated inflammation has been described in other causes of acute lung injury.46 Such interactions may also exist in TRALI. Alternatively, lung inflammation due to the “first hit” may have been too severe to discriminate between the two hits.

The effect on coagulopathy occurred after infusion with supernatant of the aged PLTs but not when washed aged PLTs were used. Of interest, plasma-stored platelets cause more transfusion complications compared to platelets stored in additive solution II.47 Further studies are required to determine whether replacement of plasma as a storage medium for PLTs or washing of aged PLTs before transfusion should be implemented.

Bioactive lipids which accumulate in the supernatant of blood products have been implicated in TRALI. We found an increase in LysoPCs and a decrease of LysoPC precursors during storage of rat platelets, as well as in aged human platelet products, which were able to prime neutrophils in vitro. These data are in line with the finding that the concentration of bio-active lipids increases during blood storage,8,9 and the finding that plasma-derived purified LysoPCs have neutrophil priming capacity.8,9,36 Also, clinical studies show an association between the concentration of lysoPCs in the transfused products and the onset of TRALI.5,13,38 Our data suggest that bio-active lipids that have accumulated during storage of PLTs may have mediated TRALI by priming of neutrophils. Of note, fresh PLTs already showed increased neutrophil priming capacity when compared to buffer control. However, fresh PLTs did not result in lung injury in our transfusion model. This may suggest that a threshold amount of LysoPCs may be needed before transfusion
results in neutrophil priming. However, it should be noted that besides lysoPCs, other mediators that are released during platelet storage but were not measured in this study, may have contributed to the inflammatory process.

Recently, it has been suggested that sCD40L accumulating during PLT storage may be involved in the pathogenesis of TRALI. Interestingly, CD40L was present in pulmonary tissue after transfusion, which seemed to be expressed by both T cells, as determined by CD3 staining, and cells lining the endothelial vascular wall. In line with these findings, it has been hypothesized that sCD40L from aged PLTs ligates CD40 on primed neutrophils, resulting in endothelial damage. As no differences were found between fresh and aged platelets, we could not confirm the role of CD40L in the onset of the lung injury in our model. However, we only measured cell-associated CD40L and we can not rule out that sCD40L may have played a role. Unfortunately, we were not able to determine the concentration of sCD40L in the aged PLTs, as no assay exists to determine sCD40L in rat plasma.

Alternatively, cytokines that accumulate during storage of cell containing blood products may cause TRALI. High levels of IL-8 have been measured in platelet concentrates implicated in TRALI reactions. However, a clinical study on TRALI could not confirm an association between high IL-8 levels and the occurrence of TRALI. We did not find elevated levels of cytokines in aged rat platelets. Of importance, it should be noted that products used in this study were leukocyte-poor before storage by our preparation method. Lastly, biochemical deterioration of the blood products, such as increase in lactate and potassium and decrease in pH, may have contributed to the observed lung injury.

An important issue is how the results from our study should be implemented in the pathogenesis of TRALI. Our results support the hypothesis that transfusion can cause lung injury in the absence of antibodies in the blood product. In accordance, the use of male-only plasma has reduced, but not prevented the occurrence of TRALI. Another interesting finding is that aged platelets are able to induce lung injury in the absence of a “first hit”, thus implying that TRALI in the absence of antibodies is not necessarily a “two hit” event. However, as PLTs were also found to augment lung injury in a “two hit” model, it may be suggested that PLTs transfusion may contribute to morbidity in patients with primed neutrophils, i.e., with an underlying inflammatory condition. Another issue is whether our results have implications for manufacturing processes and storage time of PLT products. It may not be feasible to avoid transfusion of platelets that do not cause neutrophil priming, as in vitro neutrophil priming occurred already after 2 days of storage. As washing of the aged PLTs abrogated the detrimental effect, washing of the aged PLTs as a manufacturing process may reduce pulmonary complications. However, while of theoretical benefit, recommendations for washing of platelets in the clinical setting are premature for several reasons: the process is logistically complex and
expensive, the platelet count (and hence the therapeutic efficacy) of a washed platelet product is reduced, availability of a platelet product in emergent situations would be delayed, it is unknown at what age human platelets would acquire a (theoretical) incremental risk of causing TRALI, and no clinical data exist to support the efficacy of this policy in reducing TRALI.

In conclusion, we show that aged platelets cause lung injury, in which pulmonary coagulopathy is prominent, in a “two hit” in vivo transfusion model, which may be caused by LysoPCs which have accumulated in the aged platelet products.
Reference List


